• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝细胞癌的肝动脉灌注化疗:临床进展

Hepatic Artery Infusion Chemotherapy for Hepatocellular Carcinoma: Clinical Advancements.

作者信息

Xu Wei, Li Qing, Liang Bin

机构信息

Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Hubei Key Laboratory of Molecular Imaging, Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Road, Wuhan 430022, China.

Department of Radiology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.

出版信息

Curr Oncol. 2025 May 28;32(6):313. doi: 10.3390/curroncol32060313.

DOI:10.3390/curroncol32060313
PMID:40558256
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12192279/
Abstract

Intermediate- and advanced-stage hepatocellular carcinoma (HCC) continues to present significant therapeutic challenges. Hepatic artery infusion chemotherapy (HAIC), a well-established locoregional treatment for unresectable HCC, has recently demonstrated promising clinical outcomes both as monotherapy and in combination with systemic therapies. This comprehensive review examines recent clinical advances in HAIC for HCC, with particular emphasis on evolving treatment regimens and their therapeutic efficacy.

摘要

中晚期肝细胞癌(HCC)仍然面临重大的治疗挑战。肝动脉灌注化疗(HAIC)是一种针对不可切除HCC的成熟局部区域治疗方法,最近无论是作为单一疗法还是与全身疗法联合使用,都显示出了有前景的临床疗效。这篇综述探讨了HAIC治疗HCC的最新临床进展,特别强调了不断演变的治疗方案及其疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a9b/12192279/91e3a2fffc3d/curroncol-32-00313-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a9b/12192279/04755fe0eef2/curroncol-32-00313-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a9b/12192279/91e3a2fffc3d/curroncol-32-00313-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a9b/12192279/04755fe0eef2/curroncol-32-00313-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a9b/12192279/91e3a2fffc3d/curroncol-32-00313-g002.jpg

相似文献

1
Hepatic Artery Infusion Chemotherapy for Hepatocellular Carcinoma: Clinical Advancements.肝细胞癌的肝动脉灌注化疗:临床进展
Curr Oncol. 2025 May 28;32(6):313. doi: 10.3390/curroncol32060313.
2
Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.钇-90微球放射性栓塞治疗不可切除的肝细胞癌
Cochrane Database Syst Rev. 2016 Feb 16;2:CD011313. doi: 10.1002/14651858.CD011313.pub2.
3
Interventional arterial chemotherapy versus sorafenib for advanced hepatocellular carcinoma in China: a health economic evaluation of open-label, randomised, phase 3 study.中国介入动脉化疗与索拉非尼治疗晚期肝细胞癌的对比:一项开放标签、随机、3期研究的卫生经济学评价
BMJ Open. 2025 May 27;15(5):e095508. doi: 10.1136/bmjopen-2024-095508.
4
Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma.肝动脉灌注化疗治疗晚期肝细胞癌
World J Gastroenterol. 2015 Apr 7;21(13):3843-9. doi: 10.3748/wjg.v21.i13.3843.
5
Hepatic arterial infusion chemotherapy combined with sorafenib versus sorafenib alone for advanced hepatocellular carcinoma: a systematic review and meta-analysis.肝动脉灌注化疗联合索拉非尼对比索拉非尼单药治疗晚期肝细胞癌的系统评价和荟萃分析。
Clin J Gastroenterol. 2023 Dec;16(6):793-802. doi: 10.1007/s12328-023-01860-4. Epub 2023 Sep 23.
6
Potential of neoadjuvant hepatic artery perfusion chemotherapy in improving surgical outcomes in hepatocellular carcinoma: a systematic review and meta-analysis.新辅助肝动脉灌注化疗改善肝细胞癌手术疗效的潜力:一项系统评价与荟萃分析
World J Surg Oncol. 2025 May 29;23(1):207. doi: 10.1186/s12957-025-03859-2.
7
Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma.肝动脉灌注化疗治疗晚期肝细胞癌
Asia Pac J Clin Oncol. 2010 Jun;6(2):80-8. doi: 10.1111/j.1743-7563.2010.01287.x.
8
Sequencing of systemic therapy in unresectable hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis of randomized clinical trials.系统治疗不可切除肝细胞癌的序贯治疗:随机临床试验的系统评价和贝叶斯网络荟萃分析。
Crit Rev Oncol Hematol. 2024 Dec;204:104522. doi: 10.1016/j.critrevonc.2024.104522. Epub 2024 Sep 26.
9
PD-1 inhibitor-augmented HAIC-TKI therapy in hepatocellular carcinoma with portal vein tumor thrombosis: real-world survival benefits, safety, and subgroup-specific efficacy.PD-1抑制剂增强的肝动脉灌注化疗联合酪氨酸激酶抑制剂治疗伴门静脉癌栓的肝细胞癌:真实世界的生存获益、安全性及亚组特异性疗效
Front Immunol. 2025 Jun 12;16:1602031. doi: 10.3389/fimmu.2025.1602031. eCollection 2025.
10
Efficacy and safety of first-line treatments for advanced hepatocellular carcinoma patients: a systematic review and network meta-analysis.晚期肝细胞癌患者一线治疗的疗效与安全性:一项系统评价和网状Meta分析
Front Immunol. 2024 Sep 17;15:1430196. doi: 10.3389/fimmu.2024.1430196. eCollection 2024.

本文引用的文献

1
Apatinib plus hepatic arterial infusion of oxaliplatin and raltitrexed for hepatocellular carcinoma with extrahepatic metastasis: phase II trial.阿帕替尼联合奥沙利铂和雷替曲塞肝动脉灌注化疗治疗伴有肝外转移的肝细胞癌:Ⅱ期临床试验。
Nat Commun. 2024 Oct 14;15(1):8857. doi: 10.1038/s41467-024-52700-z.
2
Combination Therapy of Lenvatinib and Hepatic Arterial Infusion Chemotherapy Using Cisplatin With Lipiodol and 5-Fluorouracil: A Potential Breakthrough Therapy for Unresectable Advanced Hepatocellular Carcinoma.仑伐替尼与使用顺铂联合碘油和5-氟尿嘧啶的肝动脉灌注化疗的联合疗法:一种针对不可切除的晚期肝细胞癌的潜在突破性疗法。
Cureus. 2024 Aug 5;16(8):e66185. doi: 10.7759/cureus.66185. eCollection 2024 Aug.
3
Safety and efficacy of percutaneous arterial port Implantation for Hepatic Arterial Infusion Chemotherapy.
经皮动脉植入式输液港用于肝动脉灌注化疗的安全性和有效性
Eur Radiol. 2025 Feb;35(2):1022-1033. doi: 10.1007/s00330-024-10887-1. Epub 2024 Jul 30.
4
Multicenter Phase II Trial of Lenvatinib plus Hepatic Intra-Arterial Infusion Chemotherapy with Cisplatin for Advanced Hepatocellular Carcinoma: LEOPARD.仑伐替尼联合肝动脉灌注顺铂化疗治疗晚期肝细胞癌的多中心II期试验:LEOPARD研究
Liver Cancer. 2023 Jul 7;13(2):193-202. doi: 10.1159/000531820. eCollection 2024 Apr.
5
Techniques and status of hepatic arterial infusion chemotherapy for primary hepatobiliary cancers.原发性肝胆癌肝动脉灌注化疗的技术与现状
Ther Adv Med Oncol. 2024 Jan 27;16:17588359231225040. doi: 10.1177/17588359231225040. eCollection 2024.
6
The Safety and Efficacy of Hepatic Arterial Infusion Chemotherapy Combined with PD-(L)1 Inhibitors and Molecular Targeted Therapies for the Treatment of Intermediate and Advanced Hepatocellular Carcinoma Unsuitable for Transarterial Chemoembolization.肝动脉灌注化疗联合PD-(L)1抑制剂及分子靶向治疗对不适用于经动脉化疗栓塞的中晚期肝细胞癌的安全性和有效性
J Hepatocell Carcinoma. 2023 Dec 12;10:2211-2221. doi: 10.2147/JHC.S441024. eCollection 2023.
7
Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition).原发性肝癌诊疗指南(2022年版)
Liver Cancer. 2023 Apr 5;12(5):405-444. doi: 10.1159/000530495. eCollection 2023 Oct.
8
Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study.卡瑞利珠单抗(一种 PD-1 抑制剂)联合阿帕替尼(一种 VEGFR-2 抑制剂)和肝动脉灌注化疗治疗巴塞罗那临床肝癌分期 C 期的肝细胞癌(三联疗法):一项 II 期研究。
Signal Transduct Target Ther. 2023 Oct 27;8(1):413. doi: 10.1038/s41392-023-01663-6.
9
Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations.中国肝细胞癌动脉化疗:共识推荐
Hepatol Int. 2024 Feb;18(1):4-31. doi: 10.1007/s12072-023-10599-6. Epub 2023 Oct 21.
10
Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibodies with Hepatic Arterial Infusion Chemotherapy or Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma.酪氨酸激酶抑制剂联合抗PD-1抗体与肝动脉灌注化疗或经动脉化疗栓塞治疗不可切除肝细胞癌
J Hepatocell Carcinoma. 2023 Oct 6;10:1735-1748. doi: 10.2147/JHC.S431917. eCollection 2023.